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The present studies determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with a clinically relevant
NSAID, celecoxib, to kill tumor cells. Celecoxib and PDE5 inhibitors interacted in a greater than additive fashion to kill multiple tumor cell
types. Celecoxib and sildenaﬁl killed ex vivo primary human glioma cells as well as their associated activated microglia. Knock down of PDE5
recapitulated the effects of PDE5 inhibitor treatment; the nitric oxide synthase inhibitor L-NAME suppressed drug combination toxicity.
The effects of celecoxib were COX2 independent. Over-expression of c-FLIP-s or knock down of CD95/FADD signiﬁcantly reduced killing
by the drug combination. CD95 activation was dependent on nitric oxide and ceramide signaling. CD95 signaling activated the JNK pathway
and inhibition of JNK suppressed cell killing. The drug combination inactivated mTOR and increased the levels of autophagy and knock
down of Beclin1 or ATG5 strongly suppressed killing by the drug combination. The drug combination caused an ER stress response; knock
down of IRE1a/XBP1 enhanced killing whereas knock down of eIF2a/ATF4/CHOP suppressed killing. Sildenaﬁl and celecoxib treatment
suppressed the growth of mammary tumors in vivo. Collectively our data demonstrate that clinically achievable concentrations of
celecoxib and sildenaﬁl have the potential to be a new therapeutic approach for cancer.
J. Cell. Physiol. 230: 1115–1127, 2015. © 2014 Wiley Periodicals, Inc.

Cyclooxygenase 2 (COX2) is one of the three prostaglandin
endoperoxide synthase enzymes which convert arachidonic
acid to prostaglandins, leading to an inﬂammatory response
(Chandrasekharan et al., 2002; Nandakishore et al., 2014;
Vosooghi and Amini, 2014). Inhibition of COX1–3 will thus
tend to suppress inﬂammation and a variety of well-established
non-steroidal anti-inﬂammatory drugs such as aspirin and
ibuprofen act to block these enzymes (Flower, 2003). More
recently developed NSAID drugs have a greater degree of
speciﬁcity for COX2 over COX1, potentially reducing
systemic toxicity due to a lack of COX1 inhibition; drugs such
as celecoxib (trade mark, Celebrex) (Swiergiel and Dunn, 2002;
Hsieh et al., 2008).
COX2 is over-expressed in several tumor types and drugs
that inhibit COX2, that is, celecoxib, can cause in a dosedependent fashion, tumor cell killing (Hsu et al., 2000; Williams
et al., 2000; Johnson et al., 2001). However, in many studies the
in vitro doses of celecoxib used to kill tumor cells are above
those achievable in human tissues after a 200–800 mg drug dose,
that is, 2.5–7.5 mM (Werner et al., 2002; see http://dailymed.
nlm.nih.gov/). There is also solid evidence that COX2
inhibitors have cancer chemo-preventative actions in patients,
for example, colorectal polyps using 400 mg BID (Kim and
Giardiello, 2011; Mao et al., 2011; Saba et al., 2013). However,
although drugs, such as celecoxib have anti-cancer effects, it has
been observed that tumor cells exhibiting low levels of COX2
can exhibit sensitivity to these agents, arguing that COX2
inhibitors are likely to have multiple COX2-independent
cellular targets in terms of their effects on cancer biology
(Grösch et al., 2001; Chuang et al., 2008; Schiffmann et al., 2008;
Bastos-Pereira et al., 2010). The reported mechanisms by
which COX2 inhibitors regulate tumor cell viability are diverse
and include altered levels of autophagy and endoplasmic
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reticulum stress signaling; increased death receptor expression
and reduced levels of c-FLIP-s; inhibition of the AKT protein
kinase; modulation of PPARg function; increased mitochondrial
injury and down-regulation of protective BCL-2 family
proteins; ceramide generation; and activation of protein kinase
G (PKG) (Liu et al., 2004; Pyrko et al., 2007; Soh et al., 2008;
Schiffmann et al., 2010; Chen et al., 2011; Huang et al., 2013;
Piplani et al., 2013; Ramer et al., 2013; Song et al., 2013).
Phosphodiesterase 5 (PDE5) inhibitors were originally
developed as agents to manipulate cardio-vascular biology that
were in parallel noted to treat erectile dysfunction (Watanabe
et al., 2002; Bruzziches et al., 2013). Inhibition of PDE5 suppresses
the degradation of cyclic GMP resulting in the activation of PKG
(Francis et al., 2010). cGMP/PKG, through its stimulatory actions
upon the ERK, p38 MAPK, JNK and NFkB pathways can increase
the expression of inducible nitric oxide synthase (iNOS), resulting
in the production of nitric oxide (NO) (Komalavilas et al., 1999;
Das et al., 2008; Choi et al., 2009). NO and cGMP/PKG have
multiple cellular targets including (to name but a few) ion channels,
receptors, phospholipases, Rho A, altered protein nitrosylation,
ceramide generation and death receptor signaling (Hayden
et al., 2001; Florio et al., 2003; Francis et al., 2010; Kots et al., 2011;
Russwurm et al., 2013).
Prior studies from our laboratories have demonstrated that
PDE5 inhibitors enhance the toxicities of multiple well
established cytotoxic chemotherapies (Das et al., 2010; Booth
et al., 2014; Roberts et al., 2014). In these studies, PDE5
inhibitors, in an NOS-dependent fashion, were shown to
enhance chemotherapy killing through activation of the CD95
death receptor pathway, the generation of reactive oxygen
species and mitochondrial dysfunction. The mechanism(s) by
which PDE5 inhibitors and chemotherapies interacted to
activate CD95 were not further explored.
The present studies grew out of those described in refs. (Das
et al., 2010; Booth et al., 2014; Roberts et al., 2014), and were
designed to determine whether PDE5 inhibitors enhanced
celecoxib toxicity in tumor cells and if so, the molecular
mechanisms by which the drugs interact. PDE5 inhibitors and
celecoxib, in an NOS-dependent and COX2-independent
fashion, killed multiple tumor cell types, including tumor stem
cells and anoikis resistant tumor cells. Cell killing required
expression of the death receptor CD95, though tyrosine
phosphorylation of the receptor was not required for the death
signal. The drug combination induced ER stress signaling and
autophagy that were both causal in tumor cell killing.
Materials and Methods
Materials
Phospho-/total-antibodies were purchased from Cell Signaling
Technologies (Danvers, MA) and Santa Cruz Biotech. (Santa Cruz,
CA). All drugs were purchased from Selleckchem (Houston, TX).
Commercially available validated short hairpin RNA molecules to
knock down RNA/protein levels were from Qiagen (Valencia, CA).
Antibody reagents, other kinase inhibitors, caspase inhibitors cell
culture reagents, and non-commercial recombinant adenoviruses
have been previously described (Park et al., 2010; Tang et al., 2012;
Cruickshanks et al., 2013). Previously characterized semiestablished GBM5/GBM6/GBM12/GBM14, glioblastoma cells
were supplied by Dr. C.D. James (University of California, San
Francisco) and Dr. J.N. Sarkaria (Mayo Clinic, Rochester, MN) and
were not further characterized by ourselves (Giannini et al., 2005).
The primary human GBM isolates (patient 1; patient 2; patient 3)
and primary human medulloblastoma isolates (HOSS1, VC312,
CON1) were obtained/isolated from discarded tumor tissue after
standard of care surgery. Patients had previously given informed
consent under an IRB protocol to the use of tumor tissue. Tumor
samples were made anonymous of all patient identiﬁers by the
VCU TDAAC prior to hand-over to the Dent laboratory.
JOURNAL OF CELLULAR PHYSIOLOGY

Methods
Cell culture and in vitro exposure of cells to drugs. All
fully established cancer lines were cultured at 37°C (5% (v/v CO2)
in vitro using RPMI supplemented with 10% (v/v) fetal calf serum
and 10% (v/v) non-essential amino acids. All primary human GBM
cells were cultured at 37°C (5% (v/v CO2) in vitro using RPMI
supplemented with 2% (v/v) fetal calf serum and 10% (v/v) nonessential amino acids at 37°C (5% (v/v CO2). GBM5/6/12/14 stem
cells were cultured in StemCell Technologies NeuroCult NS-A
Basal Medium supplemented with 20 mg/ml bFGF, 20 mg/ml EGF
and 2 mm heparin. For short-term cell killing assays and
immunoblotting, cells were plated at a density of 3  103/cm2 and
24 h after plating were treated with various drugs, as indicated. In
vitro small molecule inhibitor treatments were from a 100 mM
stock solution of each drug and the maximal concentration of
Vehicle (DMSO) in media was 0.02% (v/v). Cells were not cultured
in reduced serum media during any study.
Cell treatments, SDS-PAGE and Western blot analysis.
Cells were treated with various drug concentrations, as indicated in
the Figure legends. Samples were isolated at the indicated times and
SDS PAGE and immunoblotting was performed as described in refs
(Park et al., 2010; Tang et al., 2012; Cruickshanks et al., 2013). Blots
were observed by using an Odyssey IR imaging system (LI-COR
Biosciences, Lincoln, NE).
Recombinant adenoviral vectors; infection in vitro.
We generated and purchased previously noted recombinant
adenoviruses as per refs. (Park et al., 2010; Tang et al., 2012;
Cruickshanks et al., 2013). Cells were infected with these
adenoviruses at an approximate m.o.i. as indicated in the
Figure Legend (usually an moi of 50). Cells were incubated for 24 h
to ensure adequate expression of transduced gene products prior
to drug exposures.
Detection of cell death by Trypan Blue assay. Cells
were harvested by trypsinization with Trypsin/EDTA for 10 min
at 37°C. Harvested cells were combined with the culture media
containing unattached cells and the mixture centrifuged (800 rpm,
5 min). Cell pellets were resuspended in PBS and mixed with
trypan blue agent. Viability was determined microscopically using a
hemocytometer (Park et al., 2010; Tang et al., 2012; Cruickshanks
et al., 2013). Five hundred cells from randomly chosen ﬁelds
were counted and the number of dead cells was counted and
expressed as a percentage of the total number of cells counted.
Cell killing was conﬁrmed using the Sceptor instrument (Millipore,
Billerica, MA) with a 60 mm tip, which measured tumor cell size/sub
G1 DNA as an indication of tumor cell viability.
Soft agar colony formation assay. Tumor cells were
triturated to form single cells and were plated into soft agar in
sextuplicate using established procedures (500–1000 cells per
60 mm dish) (Cruickshanks et al., 2013). Cells were treated with
vehicle (DMSO), Celecoxib (5.0 mM), sildenaﬁl (as indicated, mM)
or the drugs combined. Twenty four hours after drug treatment,
the plates were washed with drug free media and the cover media
was replaced with drug free media. Colonies were permitted to
form over the following 20 days, after which they were stained and
colonies counted.
Assessment of autophagy. Cells were transfected with a
plasmid to express a green ﬂuorescent protein (GFP) and red
ﬂuorescent protein (RFP) tagged form of LC3 (ATG8). For analysis
of cells transfected with the GFP-RFP-LC3 construct, the GFP/
RFP-positive vesicularized cells were examined under the X40
objective of a Zeiss Axiovert ﬂuorescent microscope.
Plasmid transfection
Plasmids. Cells were plated as described above and 24 h after
plating, transfected. Plasmids (0.5 mg) expressing a speciﬁc mRNA
or appropriate vector control plasmid DNA was diluted in 50 ml
serum-free and antibiotic-free medium (1 portion for each
sample). Concurrently, 2 ml Lipofectamine 2000 (Invitrogen), was
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diluted into 50 ml of serum-free and antibiotic-free medium.
Diluted DNA was added to the diluted Lipofectamine 2000 for
each sample and incubated at room temperature for 30 min. This
mixture was added to each well/dish of cells containing 200 ml
serum-free and antibiotic-free medium for a total volume of 300 ml
and the cells were incubated for 4 h at 37°C. An equal volume of
2X medium was then added to each well. Cells were incubated for
48 h, then treated with drugs. To assess transfection efﬁciency of
plasmids we used a plasmid to express GFP and deﬁned the
percentage of cells being infected as the percentage of GFPþ cells.
For all cell lines the infection efﬁciency was >70%.
siRNA. Cells were plated in 60 mm dishes from a fresh
culture growing in log phase as described above, and 24 h after
plating transfected. Prior to transfection, the medium was
aspirated and 1 ml serum-free medium was added to each plate.
For transfection, 10 nM of the annealed siRNA, the positive sense
control doubled stranded siRNA targeting GAPDH or the negative
control (a “scrambled” sequence with no signiﬁcant homology to
any known gene sequences from mouse, rat or human cell lines)
were used (predominantly Qiagen, Valencia, CA; occasional
alternate siRNA molecules were purchased from Ambion, Inc.,
Austin, TX). Ten nanometer siRNA (scrambled or experimental)
was diluted in serum-free media. Four microliter Hiperfect
(Qiagen) was added to this mixture and the solution was mixed by
pipetting up and down several times. This solution was incubated at
room temp for 10 min, then added drop-wise to each dish. The
medium in each dish was swirled gently to mix, then incubated at
37°C for 2 h. One mililiter of 10% (v/v) serum-containing medium
was added to each plate, and cells were incubated at 37°C for 24–
48 h before re-plating (50  103 cells each) onto 12-well plates.
Cells were allowed to attach overnight, then treated with drugs
(0–48 h). Trypan blue exclusion assays and SDS PAGE/
immunoblotting analyzes were then performed at the indicated
time points.
Immunohistochemistry and live-dead assays. Immunohistochemistry and live-dead assays were performed in 96 well
plates using a Hermes Wiscan instrument (IDEA Bio-medical,
Rehovot, Israel). Cells were plated and treated with drugs for 12–
24 h as indicated in the Figure Legend. After treatment plates were
centrifuged to deposit ﬂoating cells onto the plate (800 rpm,
5 min). Cells were then either ﬁxed in place (4% paraformaldehyde
in PBS) or were subjected to live-dead assay using a commercially
available kit and performed according to the manufacturer’s
method (Life Technologies, Grand Island, NY). Cell viability was
measured using Wisoft software. Fixed cells were subjected to
Ki67/IL-6/TNFa staining using standard procedures (Park et al.,
2010).
Isolation of activated microglia. Following acquisition of
fresh GBM tumor tissue, we isolated activated microglia using
CD11b microglia microbeads (MACS, Miltenyi Biotec., San Diego,
CA). Tumor tissue was macerated and single cell suspensions
obtained using a Miltenyi neural tissue dissociation kit.
Animal studies. For studies with human mammary
carcinoma cells, athymic Nu/Nu mice (8 week old, female) were
injected, into the 4th mammary fat pad, with 1  106/1  107
BT474 cells or 3  106/1  107 BT549 cells. Tumors of 150 mm3
grew over the following month. Animals were segregated into
tumor volumes of approximate equivalent mean tumor size and
standard error. The animals were administered vehicle diluent
(cremophore), sildenaﬁl (2.5/5.0 mg/kg), celecoxib (2.5, 10 or
25 mg/kg) or the drug combination by oral gavage once every day
for 5 days. Other tumor studies used FTY720 (0.05 mg/kg). We
performed the experiment twice (n ¼ 2) with a total of 8 animals
per treatment group. Tumor volumes are measured every 2–3
days as indicated.
Mass spectrometry measurements. Equal numbers of
cells (5.98 þ/ 0.02  106) cells were treated for 6 h and lipids
were extracted. Bioactive lipid levels were quantiﬁed by liquid
chromatography–electrospray ionization–tandem mass
JOURNAL OF CELLULAR PHYSIOLOGY

spectrometry (LC-ESI-MS/MS) with a Shimadzu LC-20AD binary
pump HPLC system (Shimadzu, Kyoto, Japan) and an Applied
Biosystems 4000 QTRAP operating in a triple quadrupole mode, as
described previously (Hait NC et al., 2009).
Data analysis. Comparison of the effects of various
treatments was performed using one way analysis of variance and a
two tailed Student’s t-test. Statistical examination of in vivo animal
survival data utilized log rank statistical analyzes between the
different treatment groups. Differences with a P-value of <0.05
were considered statistically signiﬁcant. Experiments shown are
the means of multiple individual points from multiple experiments
( SEM).
Results

Initial studies examined whether there was a toxic interaction
between the PDE5 inhibitor sildenaﬁl and the non-steroidal
anti-inﬂammatory drug celecoxib. In mammary carcinoma cell
lines growing in 10% fetal calf serum, sildenaﬁl and celecoxib
interacted in a greater than additive fashion to kill parental wild
type tumor cells as well as anoikis resistant variants of these
cells at doses as low as 0.5 mM sildenaﬁl and 1 mm celecoxib
(Figs. 1A–C). A similar toxic interaction between sildenaﬁl and
celecoxib was observed in hepatoma, colorectal cancer,
glioblastoma and medulloblastoma cells (Figs. 1D and E;
Figs. S1A–S1F). Stem-like GBM12 cells and other stem-like
GBM cell derivatives expressed higher levels of CD133 and
other stem cell markers than parental GBM cells (Fig. S1 G).
Not only did sildenaﬁl and celecoxib treatment kill cells; it also
profoundly reduced tumor cell proliferation as judged by
reduced Ki67 staining (Fig. 1 F, upper IHC). In median dose
effect colony formation assays, sildenaﬁl and celecoxib
interacted in a greater than additive fashion to kill breast cancer
cells with combination index values lower than 0.70 (Fig. 1F,
lower graphs). As judged by increased phosphorylation of the
protein VASP-1 at S239 (a PKG site), following sildenaﬁl
treatment, we were increasing cGMP levels (Fig. 1G). As judged
by increased phosphorylation of the endoplasmic reticulum
stress marker eIF2a, following celecoxib treatment, we were
inducing an ER stress response (Fig. 1H). As judged by
decreased expression of the sphingosine-1-phosphate
receptor 1 (EDG-1), a target of the multiple sclerosis medicine
FTY720 (Fingolimod, Gilenya), FTY720 alone and
[sildenaﬁl þ celecoxib] treatments reduced EDG-1 expression
(Fig. 1I).
Studies were then performed to deﬁne on- and off-target
actions of our drugs and their effects on cell viability. The
chemically dissimilar PDE5 inhibitor tadalaﬁl interacted with
celecoxib to kill tumor cells (Figs. 2A and B). We noted that the
expression of PDE5 was elevated in breast, lung and liver tumor
tissue compared to matched non-tumor tissues from the same
organs arguing for a relatively more speciﬁc on-target effect in
tumor compared to normal tissues (Figs. 2C–E). The celecoxib
derivative 2,5-dimethyl celecoxib, that does not inhibit COX2,
was as efﬁcacious as celecoxib at enhancing sildenaﬁl toxicity
(Fig. 2F). Knock down of COX2 did not alter the lethality of the
sildenaﬁl and celecoxib drug combination in breast cancer cells
(Fig. 2G). Knock down of PDE5 expression enhanced celecoxib
lethality (Fig. 2H). The nitric oxide synthase (NOS) inhibitor
L-NG-Nitroarginine Methyl Ester (L-NAME) inhibited cell
killing by sildenaﬁl and celecoxib, consistent with the ability of
PDE5 inhibitors to increase iNOS and NO production
(Fig. 2I and J). Sildenaﬁl and celecoxib treatment radiosensitized
tumor cells (Fig. 2K). Collectively these ﬁndings argue that
celecoxib, in a COX2–independent fashion, promotes tumor
cell killing in cells lacking PDE5 expression and does so in an
NOS-dependent manner.
In Figure 1, we noted that celecoxib and sildenaﬁl interacted
to kill GBM/GBM stem-like cells as well as GBM cells freshly
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Fig. 1. The PDE5 inhibitor sildenafil interacts with celecoxib to kill cancer cell lines. (A) SKBR3 and BT549 cells were treated with celecoxib
(5 mM) and increasing concentrations of sildenafil (0–2 mM). SKBR3 and BT549 cells were treated with sildenafil (2 mM) and increasing
concentrations of celecoxib (0–5 mM). Cells were isolated after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM)
*P < 0.05 greater than corresponding value in vehicle control. (B) Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were
treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and viability determined by trypan blue
exclusion (n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: BT474 cells in 96 well plates
were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and viability determined using a livedead assay (red cells ¼ dead; green cells ¼ alive) (n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in vehicle control. (C) Breast
cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells
were isolated after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in
vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM).
Cells were isolated after 24 h and viability determined using a live-dead assay (red cells ¼ dead; green cells ¼ alive) (n ¼ 3, þ/ SEM) *P < 0.05
greater than corresponding value in vehicle control. (D) GBM12 cells and selected GBM12 stem cells were treated with celecoxib (CEL
5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM)
*P < 0.05 greater than corresponding value in vehicle control. Upper inset pictures GBM12 cells in 96 well plates were treated with celecoxib
(CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and viability determined using a live-dead assay (red cells ¼ dead;
green cells ¼ alive) (n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in vehicle control. (E) Medulloblastoma cells were treated
with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and viability determined by trypan blue exclusion
(n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: DAOY medulloblastoma cells in 96 well
plates were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and viability determined using a
live-dead assay (red cells ¼ dead; green cells ¼ alive) (n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in vehicle control. (F) Upper
IHC: BT549 cells in 96 well plates were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and
fixed. Immunohistochemistry was performed to determine the levels of Ki67 staining in cells under each treatment condition. Lower graphs:
BT549 triple negative breast and SUM149 triple negative inflammatory breast cancer cells were plated as single cells in sextuplicate (250–
1500 cells per plate) and treated with vehicle (DMSO), sildenafil (1–3 mM), celecoxib (5 mM) or the drugs in combination as indicated for 24 h.
The media was removed and drug free media added to the cultures. Colonies were permitted to form for 10 days after which colonies were
stained and counted (n ¼ 3 þ/ SEM). (G)–(I) Tumor cells (as indicated) were treated with sildenafil (2 mM); celecoxib (5 mM); FTY720 (50 nM)
or ATRA (150 nM). One, two and six hours after treatment cells, as indicated, were fixed in place and permeabilized. Immunohistochemistry
was performed to determine the levels of Phospho-VASP-1 (S239); Phospho-eIF2a; total EDG-1, and counter staining was with DAPI.
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Fig. 2. PDE5 inhibitors enhance celecoxib toxicity. (A) DAOY and HOSS1 medulloblastoma cells were treated with celecoxib (CEL 5.0 mM)
and/or tadalafil (TAD, 0.5 mM). Cells were isolated after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM) *P < 0.05
greater than corresponding value in vehicle control. (B) SKBR3 and BT474 breast cancer cells were treated with celecoxib (CEL 5.0 mM) and/
or tadalafil (TAD, 0.5 mM). Cells were isolated after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM) *P < 0.05 greater
than corresponding value in vehicle control. (C)–(E) We purchased tissue arrays of mammary/lung/liver carcinoma and matching normal
tissues. Tissue was de-parafinized, blocked and stained for expression of PDE5. The data shows representative images of matched normal and
tumor tissue. (F) Tumor cells were treated with 2,5 dimethyl celecoxib (25DMC 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated
after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in vehicle control.
(G) SUM149 cells were transfected with a scrambled siRNA (siSCR) or an siRNA to knock down COX2. Thirty-six hours after transfection
cells were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 24 h and viability determined by trypan
blue exclusion (n ¼ 3, þ/ SEM) *P < 0.05 greater than corresponding value in vehicle control. (H) BT549 cells were transfected with a
scrambled siRNA (siSCR) or an siRNA to knock down PDE5. Thirty-six hours after transfection cells were treated with increasing
concentrations of celecoxib (0–7.5 mM). Cells were isolated after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM)
*P < 0.05 greater than corresponding value in siSCR control. (I) and (J) BT549, BT474 breast and HOSS1 medulloblastoma cells were
pre-treated with vehicle or the NOS inhibitor L-NAME (1 mM). After 30 min, cells were treated with celecoxib (CEL 5.0 mM) and/or sildenafil
(SIL, 2.0 mM). Cells were isolated after 24 h and viability determined by trypan blue exclusion (n ¼ 3, þ/ SEM) *P < 0.05 greater than vehicle
control; #P < 0.05 less than corresponding value in vehicle control. (K) BT474 and BT549 cells were plated as single cells in sextuplicate.
Twelve hours after plating cells were treated with vehicle (DMSO), celecoxib (2 mM), sildenafil (1 mM) or the drugs in combination as
indicated. Thirty minutes after drug treatment cells were irradiated (2 Gy) or mock exposed (time out of incubator 20 min). The media was
replaced after 12 h with drug free media and colonies permitted to form over the following 10 days. Colonies were fixed, stained and counted
(n ¼ 3 þ/ SEM). #P < 0.05 less than corresponding value in unirradiated cells.

isolated from patients. The growth of all tumors is inﬂuenced
by stromal cell signaling; in the brain activated, microglia play a
pivotal role in the proliferation and invasive potential of
malignant glial tumors. Hence, we next examined the impact of
sildenaﬁl and celecoxib treatment on activated microglia
freshly isolated from GBM tumors ex vivo and on the synthesis
of paracrine ligands by the activated microglia. Celecoxib and
sildenaﬁl interacted in a greater than additive fashion to kill
activated microglia (Fig. S2A). Treatment of activated microglia
with celecoxib and sildenaﬁl rapidly reduced expression of
JOURNAL OF CELLULAR PHYSIOLOGY

interleukin 6 and of tumor necrosis factor a (Fig. S2B). Thus,
sildenaﬁl and celecoxib treatment has the potential to kill
activated stromal cells in the brain and to suppress their
production of growth promoting and inﬂammatory
cytokines.
We next examined the roles signal transduction pathways
play in regulating the response of tumor cells to sildenaﬁl and
celecoxib treatment. Drug combination exposure almost
abolished ERK1/2 activity and reduced phosphorylation of
AKT, mTOR, p70 S6K and p65 NFkB at regulatory sites
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Fig. 3. The toxic interaction between PDE5 inhibitors and celecoxib is regulated by ERK, AKT, p70 S6K, p38 MAPK and mTOR. (A) BT549
cells were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were isolated after 12 h and lysates prepared for SDS
PAGE and immunoblotting against the indicated phospho-proteins and proteins. (B) HCT116 colon cancer cells (Wild-type cells expressing KRAS D13; null / cells with K-RAS D13 deleted; null cells expressing H-RAS V12; null cells expressing H-RAS V12–35 that activates RAF-1;
null cells expressing H-RAS V12–40 that activates PI3K) were treated with vehicle (DMSO), celecoxib (5.0 mM), sildenafil (2 mM) or the drugs
combined. Twenty-four hours after drug treatment cells were isolated and viability determined by trypan blue exclusion assay (n ¼ 3 þ/
SEM). *P < 0.05 greater than vehicle control; **P < 0.05 greater than corresponding value in HCT116 / H-RAS V12 cells. (C) BT549 cells
were infected with recombinant adenoviruses to express empty vector (CMV); constitutively active AKT; dominant negative AKT (50 moi).
Twenty-four hours after infection cells were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug
treatment cells were isolated and viability determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). *P < 0.05 greater than corresponding
value in CMV infected cells; #P < 0.05 less than corresponding value in CMV infected cells. (D) BT549 cells were infected with recombinant
adenoviruses to express empty vector (CMV); constitutively active MEK1; dominant negative MEK1 (50 moi). Twenty-four hours after
infection cells were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug treatment cells were
isolated and viability determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). *P < 0.05 greater than corresponding value in CMV infected
cells; #P < 0.05 less than corresponding value in CMV-infected cells. (E) BT549 cells were transfected with plasmids to express empty vector
(CMV); constitutively active p70 S6K; constitutively active mTOR; dominant negative p38. Twenty-four hours after transfection cells were
treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug treatment cells were isolated and viability
determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). *P < 0.05 greater than corresponding value in CMV transfected cells; #P < 0.05 less
than corresponding value in CMV transfected cells. (F) BT549 and HOSS1 cells were pre-treated with vehicle (DMSO) or the JNK inhibitory
peptide (JNK-IP, 10 mM). Cells were then treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug
treatment cells were isolated and viability determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). *P < 0.05 greater than celecoxib
treatment alone; #P < 0.05 less than corresponding value in vehicle treated cells. (G) GBM5/6/12/14 cells as indicated pre-treated with vehicle
or the NOS inhibitor L-NAME (1 mM). After 30 min cells were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Cells were
isolated after 12 h and the phosphorylation of JNK and total JNK expression determined.

(Fig. 3A). Initially, we made use of HCT116 colon cancer cells
expressing in wild-type cells a mutant active K-RAS D13 or
mutant forms of H-RAS V12 that speciﬁcally activated RAF-1 or
PI3K (Car
on et al., 2005). Expression of H-RAS V12 protected
cells from celecoxib and sildenaﬁl toxicity to a greater extent
than did expression of K-RAS D13. The protective effect of HRAS V12 was lost in cells expressing a mutant H-RAS V12
protein that speciﬁcally activated only RAF-1 or a H-RAS V12
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protein that speciﬁcally activated only PI3K (Fig. 3B). In
BT549 breast cancer cells which are null for phosphatase
and tensin homolog (PTEN), expression of activated AKT or
MEK1 signiﬁcantly reduced drug combination toxicity and
expression of dominant negative AKT or MEK1 enhanced
drug combination lethality (Figs. 3C and D). Expression of
activated forms of p70 S6K or mTOR also suppressed drug
combination killing, as did inhibition of JNK signaling
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(Figs. 3E and F). Surprisingly, expression of dominant negative
p38 MAPK enhanced drug toxicity. Incubation of cells with the
NOS inhibitor L-NAME suppressed both sildenaﬁl-induced and
(sildenaﬁl þ celecoxib)-induced activation of JNK (Fig. 3G).
We next deﬁned the cell survival regulatory pathways by
which celecoxib and sildenaﬁl interacted to kill tumor cells.
Inhibition of the intrinsic apoptosis pathway by overexpression of BCL-XL or expression of dominant negative
caspase 9 reduced cell killing (Figs. 4A and B). Of note, however
was that, over-expression of the caspase 8 inhibitor c-FLIP-s
also protected cells, suggestive that the extrinsic apoptosis
pathway was being activated. In general, agreement with the
hypothesis that the extrinsic pathway was being activated,
knock down of the docking protein FAS associated death
domain (FADD) or of the death receptor CD95 attenuated the
toxic interaction between sildenaﬁl and celecoxib (Fig. 4C). In
further agreement with a role for CD95 in the killing process,
drug combination exposure caused a rapid plasma membrane
localization and clustering of CD95, indicative of receptor
activation (Fig. 4D). Of particular note, whilst knock down of
FAS-Ligand reduced killing by 50% use of a neutralizing antiFAS-L antibody had no impact on cell killing, despite the
antibody being able to block exogenous FAS-L killing (Figs. 4E
and F, data not shown). Thus, the mechanisms by which knock
down of total FAS ligand expression can alter CD95 signaling
remain to be resolved. Incubation of cells with the NOS
inhibitor L-NAME prevented CD95 plasma membrane
localization (Fig. 4G). There are multiple mechanisms by which
CD95 can become activated including the actions of ceramides
for receptor clustering and tyrosine phosphorylation for
receptor oligomerization (Eberle et al., 2007; Park et al., 2010).
To test whether tyrosine phosphorylation of CD95 played a
role in sildenaﬁl/celecoxib biology, we utilized HuH7 hepatoma
cells that are CD95 null together with constructs to express
either wild-type CD95 or a CD95 protein that lacks the two
sites of regulatory tyrosine phosphorylation (CD95 Y232F
Y291F) (Hamed et al., 2013). Regardless of tyrosine
phosphorylation status, expression of CD95 facilitated the
toxic interaction between sildenaﬁl and celecoxib (Fig. 4H).
Studies from our laboratory using the non-coxib derivative
of celecoxib, OSU-03012, have shown that this compound kills
tumor cells through the induction of endoplasmic reticulum
(ER) stress and autophagy (Yacoub et al., 2006; Park et al., 2008;
Booth et al., 2012). Initial studies to examine autophagy in the
present studies made use of cells transfected to express an
LC3-GFP-RFP construct. Treatment of cells with sildenaﬁl and
celecoxib increased the numbers of early autophagosome
GFPþ and late RFPþ autolysosome vesicles in cells suggestive
that autophagic ﬂux was being induced (Fig. 5A). Incubation of
cells with the nitric oxide synthase inhibitor L-NAME
suppressed the drug-induced induction of GFPþ and RFPþ
vesicles (Fig. 5B). Knock down of the autophagy regulatory
proteins Beclin1 or ATG5 abolished the induction of autophagy
and signiﬁcantly reduced the toxicity of sildenaﬁl and celecoxib
treatment (Fig. 5C, data not shown). We next examined the
role of ER stress signaling in the cellular response to sildenaﬁl
and celecoxib treatment. Inhibition of the IRE1/XBP1 arm of
the ER stress response increased the toxicity of sildenaﬁl and
celecoxib treatment (Figs. 5D and E). Inhibition of the eIF2a/
ATF4 arm of the ER stress response almost abolished the
lethality of sildenaﬁl and celecoxib treatment; knock down of
CHOP had a more modest effect at reducing cell killing. The
data with eIF2a knock down correlated with the drug
combination causing increasing phosphorylation of eIF2a
(Fig. 5D, inset panel; see also data in Fig. 1). Expression of a
dominant negative form of eIF2a (S51A) protected cells from
sildenaﬁl and celecoxib treatment toxicity whereas expression
of an activated mutant of eIF2a (S51D) enhanced drug-induced
killing (Fig. 5F). Inhibition of eIF2a or CD95 function (knock
JOURNAL OF CELLULAR PHYSIOLOGY

down) suppressed the activation of JNK caused by sildenaﬁl and
celecoxib treatment (Fig. 5G [cf data in Fig. 3F]).
The generation of ceramide species is known to play an
important role in the activation of CD95 and JNK following
exposure to a variety of stressful stimuli. We and others have
previously shown that ceramide generation can mediate CD95
activation (Park et al., 2010). Indeed, inhibition of de-novo
ceramide synthesis using fumonisin B1 reduced drug-induced
activation of both CD95 and JNK, and suppressed killing by the
drug combination (Figs. S3A and B). Intriguingly, 6 h after
celecoxib exposure, dihydro-ceramide levels signiﬁcantly
increased (indicative of ceramide synthase 2/3/6 activation)
(Fig. S3C) and dihydro-sphingosine-1-phosphate levels were
decreased (Fig. S3D). Both of these changes in dihydro
sphingolipids were at least partially prevented by pretreatment with the nitric oxide synthase inhibitor L-NAME
(Figs. S3C–H). However, of particular concern was that as a
single agent, celecoxib increased the levels of sphingosine-1phosphate (Fig. S3H). Knock down of ceramide synthase 6, but
not ceramide synthase 2, reduced cell killing by the drug
combination (Fig. S3I).
Based on our data in Fig. S3A–I, we determined whether
treatment of [celecoxib þ sildenaﬁl] cells with clinically
relevant FDA approved agents which also increase ceramide
levels and reduce sphingosine-1-phosphate levels could further
enhance the killing effect caused by [celecoxib þ sildenaﬁl].
FTY720 (Fingolimod, Gilenya) is an FDA approved drug for the
treatment of multiple sclerosis that acts to suppress
sphingosine-1-phosphate signaling processes as well as
sphingosine-1-phosphate production and also causes an
increase in ceramide levels (see data in Fig. 1). FTY720 can also
act as a histone deacetylase inhibitor against HDAC1 and
HDAC2 and prior studies from our laboratory have shown that
HDAC inhibitors increase expression of CD95 (Park et al.,
2010; Cruickshanks et al., 2013). Fenretinide (4HPR) is a much
trialed synthetic chemical related to vitamin A that inhibits the
desaturase enzyme which metabolizes dihydro-ceramides, and
which has been shown to both concentrate in the breast and to
reduce breast cancer relapse in pre-menopausal women
(Formelli et al., 1993; Sabichi et al., 2003; Veronesi et al., 2006;
Wang et al., 2008; Shin et al., 2012; Holliday et al., 2013). ATRA
(all-trans retinoic acid) is also a vitamin A analogue that is a
highly effective therapeutic agent in acute promyelocitic
leukemia patients.
Treatment of mammary tumor cells with clinically relevant
concentrations of FTY720 (50 nM) rapidly increased the
levels of multiple dihydro-ceramide species (Fig. S3J). At
clinically relevant single agent concentrations that lacked
individual toxicity, FTY720 or 4HPR signiﬁcantly enhanced the
lethality of [celecoxib þ sildenaﬁl] treatment in multiple tumor
cell types (Figs. S3K–M). Similar data to that with FTY720 or
4HPR were also observed using ATRA (Fig. S3N).
FTY720 is known to act as an HDAC inhibitor, and prior
studies from our group have demonstrated that multiple
HDAC inhibitors can increase expression of CD95. In
agreement with FTY720 being an HDAC inhibitor, the
acetylation of histones in treated tumor cells was increased by
the drug which was also associated with increased expression
of CD95 (Fig. S3O). Knock down of HDAC1 and HDAC2, the
HDACI targets of FTY720, also increased CD95 expression,
and knock down of CD95 or incubation of cells with fumonisin
B1 suppressed killing by FTY720 þ celecoxib þ sildenaﬁl
treatment (Fig. S3P). Similar data were obtained using 4HPR
and ATRA (Figs. S3Q and R).
As noted for [celecoxib þ sildenaﬁl] treatment previously,
treatment of cells with [celecoxib þ sildenaﬁl þ FTY720] had a
radiosensitizing effect (Fig. S3S). Finally, based on prior and
present knowledge that FTY720 increases ceramide levels and
that 4HPR inhibits ceramide degradation, we compared the
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Fig. 4. Celecoxib and sildenafil-induced lethality is suppressed by inhibition of the intrinsic and extrinsic apoptosis pathways. (A) and (B)
BT549, HOSS1 and DAOY cells were infected with recombinant adenoviruses to express empty vector (CMV); dominant negative caspase 9;
BCL-XL; or c-FLIP-s. Twenty-four hours after infection cells were then treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM).
Twenty-four hours after drug treatment cells were isolated and viability determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). #P < 0.05
less than corresponding value in CMV infected cells. (C) BT549 and HOSS1 cells were transfected with a scrambled control siRNA (siSCR) or
siRNA molecules to knock down expression of CD95 (siCD95) or FADD (siFADD). Thirty-six hours after transfection cells were then treated
with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug treatment cells were isolated and viability
determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). #P < 0.05 less than corresponding value in siSCR transfected cells. (D) BT549 and
HOSS1 cells in 96 well plates were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Six hours after treatment cells were
fixed to the plate and immunohistochemistry performed to determine the plasma membrane levels of CD95. The upper images obtained
using the Hermes Wiscan imaging system is representative of the data. The intensity of CD95 immunostaining was determined using the
Wisoft data analysis package (n ¼ 3 þ/ SEM). *P < 0.05 value greater than celecoxib treatment alone. (E) and (F) BT474 and BT549 cells were
transfected with scrambled siRNA (siSCR) or siRNA molecules to knock down expression of FAS-L or FADD, as indicated. Thirty-six hours
after transfection cells were treated with a control IgG antibody (10 mg) or with a neutralizing anti-FAS-L antibody (NOK-1). Cells were then
treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug treatment cells were isolated and viability
determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). #P < 0.05 less than corresponding value in siSCR transfected cells. (G) BT549 in 96
well plates were pre-treated with vehicle or L-NAME (1 mM). Cells were then treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL,
2.0 mM). Six hours after treatment cells were fixed to the plate and immunohistochemistry performed to determine the plasma membrane
levels of CD95. The intensity of CD95 immunostaining was determined using the Wisoft data analysis package (n ¼ 3 þ/ SEM). *P < 0.05 value
greater than celecoxib treatment alone; #P < 0.05 less than corresponding value in vehicle-treated cells. (H) HuH7 cells were transfected with
either an empty vector plasmid (CMV); a plasmid to express CD95-GFP or a plasmid to express CD95-GFP-Y232F Y291F (46,47). Twentyfour hours after transfection cells were then treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug
treatment cells were isolated and viability determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). *P < 0.05 greater than corresponding
value in CMV transfected cells.
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Fig. 5. Sildenafil and celecoxib increase autophagy and promote ER stress which regulate the cell killing process. (A). BT549 and HOSS1 cells
were transfected with a plasmid to express LC3-GFP-RFP. Twenty-four hours after transfection cells were then treated with celecoxib (CEL
5.0 mM) and/or sildenafil (SIL, 2.0 mM). Six hours after drug treatment cells were analyzed for the numbers of GFPþ and RFPþ intense staining
vesicles per cell (n ¼ 3 þ/ SEM). (B) BT474 cells were transfected with a plasmid to express LC3-GFP-RFP. Twenty-four hours after
transfection cells were pre-treated with vehicle or the NOS inhibitor L-NAME (1 mM). After 30 min cells were treated with celecoxib (CEL
5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twelve hours after drug treatment cells were analyzed for the numbers of GFPþ and RFPþ intense
staining vesicles per cell (n ¼ 3 þ/ SEM). #P < 0.05 less than corresponding value in vehicle treated cells; *P < 0.05 greater than vehicle
treatment. (C) BT549 and HOSS1 cells were transfected with a scrambled control siRNA (siSCR) or siRNA molecules to knock down
expression of Beclin1 (siBeclin1) or ATG5 (siATG5). Thirty-six hours after transfection cells were then treated with celecoxib (CEL 5.0 mM)
and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug treatment cells were isolated and viability determined by trypan blue exclusion
assay (n ¼ 3 þ/ SEM). #P < 0.05 less than corresponding value in siSCR transfected cells. (D) and (E) BT549 and HOSS1 cells were transfected
as indicated to with a scrambled siRNA (siSCR) or siRNA molecules to knock down expression of ATF6 (siATF6), XBP1 (siXBP1), IRE1a
(siIRE1a), eIF2a (sieIF2a), ATF4 (ATF6), or CHOP (siCHOP). Thirty-six hours after transfection cells were then treated with celecoxib (CEL
5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug treatment cells were isolated and viability determined by trypan blue
exclusion assay (n ¼ 3 þ/ SEM). #P < 0.05 less than corresponding value in siSCR transfected cells *P < 0.05 greater than corresponding value
in siSCR transfected cells. Inset Panel: BT549 cells were treated with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM) and isolated after
12 h to determine the phosphorylation of eIF2a. (F) BT549 cells were transfected with an empty vector plasmid (CMV); a plasmid to express
eIF2a S51A (dominant negative); a plasmid to express eIF2a S51D (activated). Twenty-four hours after transfection cells were then treated
with celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Twenty-four hours after drug treatment cells were isolated and viability
determined by trypan blue exclusion assay (n ¼ 3 þ/ SEM). #P < 0.05 less than corresponding value in CMV transfected cells *P < 0.05 greater
than corresponding value in CMV transfected cells. (G) BT549 cells were transfected as indicated with a scrambled siRNA (siSCR) or siRNA
molecules to knock down expression of CD95 (siCD95) or eIF2a (sieIF2a). Thirty-six hours after transfection cells were then treated with
celecoxib (CEL 5.0 mM) and/or sildenafil (SIL, 2.0 mM). Six hours after drug treatment cells were isolated and subjected to SDS PAGE and
immunoblotting to determine the phosphorylation of JNK.
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ability of FTY720 and 4HPR treatment to enhance
[celecoxib þ sildenaﬁl] toxicity. Combined treatment of tumor
cells with FTY720 and 4HPR and with [celecoxib þ sildenaﬁl]
resulted in profound levels of cell killing at times 9 h after
exposure (Fig. S3T). Of note, both fumonisin B1 and myriocin
prevented killing by [CEL/SIL/FTY] but myriocin only partially
protected cells from [CEL/SIL/FTY/4HPR] (Fig. S3T).
We next determined whether our in vitro data with
sildenaﬁl and celecoxib and with
[sildenaﬁl þ celecoxib] þ FTY720 translated into animal model
systems (Fig. 6). In our ﬁrst series of studies, we injected
1  106 cells and pre-formed large mammary tumors in the fat
pads of female athymic mice (150 mm3). Animals were
treated for 6 days with either vehicle, sildenaﬁl, celecoxib or
both drugs simultaneously. Treatment of animals with
celecoxib and sildenaﬁl signiﬁcantly reduced the growth of
tumors below that of celecoxib alone (Fig. 6A). In the second
series of studies, we injected 3  106 cells and 4 days after
injection animals were treated for 7 days with either vehicle,
sildenaﬁl, celecoxib or both drugs simultaneously. Treatment
of animals with celecoxib and sildenaﬁl signiﬁcantly reduced the
formation and growth of tumors below that of celecoxib alone
(Fig. 6B). Similar data to that in Fig. 6A were obtained using
triple negative BC cells treated with drugs for 5 days (Fig. 6C).
We next injected 1  107 BT549 cells into the fat pad and 4
days after injection tumors of 150 mm3 had formed, and
animals were treated with either vehicle,
[sildenaﬁl þ celecoxib], FTY720 or all three drugs
simultaneously. Treatment of animals with celecoxib and
sildenaﬁl and FTY720 signiﬁcantly reduced the growth of
tumors below that of celecoxib and sildenaﬁl alone (Fig. 6D).
This was associated with increased animal survival (Fig. 6E).
Similar data to that in breast cancer was observed in GBM (Fig.
S3U). Of note, treatment of animals with higher doses of
sildenaﬁl and celecoxib and FTY720 above those used in tumor
studies and for the same amount of time did not cause
noticeable normal tissue toxicity as judged using H&E staining
(Fig. S4). Thus sildenaﬁl and celecoxib treatment safely
suppresses BC and GBM tumor growth in vivo which is
enhanced by the FDA approved multiple sclerosis drug FTY720
(Fingolimod, Gilenya).
Discussion

The present studies were performed to determine whether
clinically relevant PDE5 inhibitors interacted with the COX2
inhibitor celecoxib to kill cancer cells. In multiple tumor cell
types, including anoikis resistant and stem cell-like cells,
sildenaﬁl (and tadalaﬁl) interacted with celecoxib to promote
killing in short-term assays and long-term colony formation
assays. Knock down of PDE5 recapitulated the combinatorial
effect of a PDE5 inhibitor when combined with celecoxib. PDE5
inhibitors are known to enhance cGMP and NO levels;
inhibition of NOS enzymes by L-NAME prevented the killing
interaction between sildenaﬁl and celecoxib. Our data also
argued that celecoxib was acting in a COX2-independent
manner when combined with sildenaﬁl to promote cell death.
Thus celecoxib, in a COX2–independent fashion, promotes
tumor cell killing in cells lacking PDE5 expression and does so in
an NOS-dependent manner.
The molecular mechanisms by which sildenaﬁl and celecoxib
interact to kill were then investigated. Drug combination
treatment tended to inactivate signaling pathways normally
associated with cell survival (ERK, AKT, p70 S6K, mTOR,
NFkB) and to activate pathways normally associated with cell
killing (JNK, p38 MAPK). Based on the use of site speciﬁc RAS
mutants and molecular tools, we noted that combined signaling
by ERK and AKT, or activation of mTOR, was required to
prevent the synergy of drug interaction. Of note, others have
JOURNAL OF CELLULAR PHYSIOLOGY

argued that NO-induced DNA damage through ATM can
suppress mTOR function (Tripathi et al., 2013). Inhibition of
p38 MAPK and to a greater extent JNK blocked cell killing by
the combination. As noted above, L-NAME prevented the
killing interaction between sildenaﬁl and celecoxib, and
incubation of cells with the NOS inhibitor L-NAME blocked
JNK activation.
The cell death pathway(s) by which sildenaﬁl and celecoxib
interacted to kill were also determined. Inhibition of both the
intrinsic and extrinsic apoptosis pathways reduced killing. The
drug combination activated the death receptor CD95 in a
tyrosine phosphorylation independent fashion and knock down
of CD95 or FADD suppressed the toxic drug interaction. JNK
activation, already shown to be a toxic signal, was CD95
dependent. And, activation of CD95 was suppressed by
inhibition of NOS enzymes using L-NAME. Thus, celecoxib and
sildenaﬁl in an NOS-dependent fashion activate CD95 which
plays a key role in the activation of JNK which signals towards
cell death. Studies by others have shown that nitrosylation of
CD95 at its regulatory tyrosine residues inhibits CD95
signaling (Reinehr et al., 2004). Others, however, have argued
that NO signaling and CD95 activation can cooperate to induce
cell death (Gandelman et al., 2013; Gonzalez et al., 2013). The
precise mechanism(s) by which NO signaling regulates CD95
function in our system in combination with celecoxib will
require studies beyond the scope of the present manuscript.
In addition to activating the extrinsic apoptosis pathway, the
drug combination also increased the numbers of
autophagosomes and autolysosomes, that is, “autophagy,” in a
time-dependent fashion that was inhibited by incubation of the
cells with L-NAME. Inhibition of autophagy suppressed cell
killing. NO signaling has been linked by others to the regulation
of autophagy; in some primary non-transformed cells, NO can
inhibit autophagy by inhibiting JNK signaling (Benavides et al.,
2013; Shen et al., 2014). In some transformed cells, NO
signaling can promote autophagy in an mTOR-dependent
fashion which seems to play a role in tumor cell killing (Yu et al.,
2012; Tripathi et al., 2013). We discovered that the drug
combination inactivated mTOR, and expression of an activated
form of mTOR suppressed killing, as well as autophagy as
judged by GFPþ and RFPþ cells (unpublished data). The
inactivation of mTOR was also blocked by incubation with
L-NAME (unpublished data). Thus nitric oxide signaling plays a
key role in both de-repressing a brake on toxic autophagy
(mTOR) as well as promoting activation of the CD95/JNK
apoptosis pathway.
The regulation of CD95 activation has been proposed to
require tyrosine phosphorylation of the receptor but also the
generation of ceramide species (e.g., Cremesti et al., 2001). In
prior studies by our group using different therapeutic drug
combinations, we have found that ceramide synthase
6-mediated generation of ceramide played an important role in
CD95 activation and tumor cell killing (e.g., Park et al., 2010).
Celecoxib and sildenaﬁl treatment increased the levels of
[C16:0, C24:1, C24:0] dihydro-ceramide species; indicative
that ceramide synthases 2, 3 and 6 were activated. Pan
inhibition of ceramide synthase activity using fumonisin B1
suppressed the activation of CD95 and JNK, and enhanced
levels of autophagy. Knock down of ceramide synthase 6
protected cells from drug combination toxicity. In smooth and
cardiac muscle cells, inhibition of ceramide synthase enzymes
blocks nitric oxide toxicity (Rabkin, 2002; Pilane and LaBelle,
2004).
Recently, several studies have demonstrated that inhibitors
of ceramide desaturase, the last enzyme in the de novo
synthesis of ceramide, also elevate levels of dihydro-ceramide
species and consequently induce cell killing and autophagy of
diverse cancer cell lines, that is, the vitamin A analogue
fenretinide (4HPR). And in addition, FTY720 is known to
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Fig. 6. Sildenafil and celecoxib interact to suppress mammary tumor growth in vivo. Panel A. BT474 cells (1  106) were injected into the 4th
mammary fat pad of athymic mice and tumors permitted to form for 21 days until the mean tumor volume was 150 mm3. Animals were
segregated into groups with very similar mean tumor volumes. Animals were treated with vehicle (cremophore), sildenafil (5 mg/kg),
celecoxib (10 mg/kg) or both drugs simultaneously for 5 days QD. Tumor volumes were measured every third day and the –Fold increase in
tumor volume calculated (with Day 0 ¼ 1.00) (2 studies, 8 animals total per group þ/ SEM) *P < 0.05 lower than celecoxib alone value.
Panel B. BT474 cells (3  106) were injected into the 4th mammary fat pad of athymic mice and 4 days after injection animals were randomly
segregated into four groups. Animals were treated with vehicle (cremophore), sildenafil (5 mg/kg), celecoxib (10 mg/kg) or both drugs
simultaneously for 7 days QD. Tumor volumes were measured beginning at Day 7 and then every second day and the actual increase in
tumor volume calculated (with Day 0 ¼ 0 mm3) (2 studies, 8 animals total per group þ/ SEM) *P < 0.05 lower than celecoxib alone value.
Panel C. BT549 cells (1  106) were injected into the 4th mammary fat pad of athymic mice and tumors permitted to form for 21 days until the
mean tumor volume was 150 mm3. Animals were segregated into groups with very similar mean tumor volumes. Animals were treated with
vehicle (cremophore), sildenafil (5 mg/kg), celecoxib (25 mg/kg) or both drugs simultaneously for 5 days QD. Tumor volumes were measured
every third day and the –Fold increase in tumor volume calculated (with Day 0 ¼ 1.00) (2 studies, 8 animals total per group þ/ SEM) *P < 0.05
lower than celecoxib alone value. Panel D. BT549 cells (1  107) were injected into the 4th mammary fat pad of athymic mice and tumors
permitted to form until the mean tumor volume was 150 mm3. Animals were segregated into groups with very similar mean tumor
volumes. Animals were treated with vehicle (cremophore), (sildenafil (2.5 mg/kg) and celecoxib (2.5 mg/kg)) and/or FTY720 (0.05 mg/kg)
simultaneously for 7 days QD. Tumor volumes were measured approximately every third day and the tumor volume calculated (with Day
0 ¼ 1.00) (2 studies, 8 animals total per group þ/ SEM) *P < 0.05 lower than celecoxib þ sildenafil value. Panel E. Kaplan–Meir survival curves
based on data presented in Panel D. #greater survival that vehicle-treated animals; ##greater survival than [celecoxib þ sildenafil] treatment
alone.
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decrease sphingosine-1-phosphate signaling and to increase
dihydro-ceramide levels. Our data demonstrated that either
4HPR, ATRA or FTY720 at clinically achievable concentrations
could enhance the lethality of [celecoxib þ sildenaﬁl]
treatment in vitro and in vivo. These ﬁndings suggest that the
planned for clinical translation of the celecoxib and sildenaﬁl
concept should also possibly include a lagging arm of the trial in
which the toxicity of a three drug combination with FTY720 (or
ATRA) is determined. Unfortunately Novartis, the makers of
Fingolimod, do not wish to support the oncologic translation of
this drug due to its ﬁnancial relevance to the company and the
possible discovery of additional contraindications in cancer
patients. As Fingolimod/Gilenya (standard of care, 0.5 mg/day
per patient) costs $7,500/month, it is highly unlikely that our
three drug combination approach will reach the clinical arena in
the foreseeable future. Additional studies will also be required
to determine whether ceramide synthase and desaturase
enzyme activities are regulated by protein nitration or by
celecoxib-induced ER stress signaling.
Celecoxib levels in human plasma and tissues after a
200–800 mg single dose can reach up to 2.5–7.5 mM and
it is evident that the drug at these concentrations has chemopreventative effects in patients. Although, the majority of
celecoxib is albumin bound in plasma after a 200–800 mg single
dose, the partitioning of celecoxib into multiple organs occurs
rapidly and after 5 days of dosing the levels of celecoxib in the
plasma and in tissues reach equilibrium at 5–10 mM. This
delivery and partitioning process is similar in concept to the
delivery of paclitaxel using albumin as a carrier (i.e., Abraxane).
As celecoxib has been safely dosed on a daily basis at up to
2,600 mg QD for 2 weeks our in vitro studies using 5 mM
celecoxib will be well within the physiologically achievable
range of free drug in a human tumor. Sildenaﬁl has been safely
administered to patients at doses of up to 200 mg, with peak
plasma levels in the 3 mm range and a bioavailability of 40%
(Nichols et al., 2002). Our data in Figure 1 would argue that at
sildenaﬁl concentrations as low as 0.5 mM, we can observe a
signiﬁcant interaction with celecoxib, again suggesting that we
are within the physiologically achievable range of free drug.
Similarly, using clinically achievable concentrations of 4HPR
(200 nM), ATRA (150 nM) and FTY720 (50 nM) we were able
to demonstrate drug interactions in vitro and in vivo. As
FTY720 is known to concentrate in the brain (and lung and
adipose tissue) our data strongly argue that the clinical
translation of [celecoxib þ sildenaﬁl þ FTY720] in mammary
tissue in situ, NSCLC and GBM should be explored.
Celecoxib at much higher concentrations than used in the
present studies has been reported to cause ER stress signaling
(Tsutsumi et al., 2004; Kardosh et al., 2008; Chen et al., 2010).
We noted that whilst celecoxib as a single agent at 5 mm did not
strongly increase eIF2a phosphorylation the drug combination
did increase the phosphorylation of eIF2a, and we then
interrogated the three arms of the ER stress response as to
whether they controlled the level of cell killing. Inhibition of the
IRE1a/XBP1 arm of the stress response enhanced both
celecoxib and (celecoxib þ sildenaﬁl) lethality whereas
inhibition of the eIF2a/ATF4/CHOP arm of the response
protected cells. Celecoxib at 10-fold higher levels, through an
eIF2a/ATF4/CHOP pathway, has been proposed to increase
expression of the death receptor DR5 (Oh et al., 2010). Others
have shown celecoxib to increase CD95 levels (Kern et al.,
2006). Thus, it is probable that our observed activation of death
receptor signaling may be augmented in the long term by
signaling by newly synthesized death receptors. Additional
studies beyond the scope of this manuscript will be required to
identify the proteins downstream of the IRE1a/XBP1 arm of
the ER stress response that control the apoptotic threshold.
In conclusion, we have discovered that the approved NSAID
celecoxib can interact with approved PDE5 inhibitors to kill a
JOURNAL OF CELLULAR PHYSIOLOGY

wide range of tumor cell types at physiologically relevant
concentrations. In some Westerner European nations, it has
frequently been difﬁcult for cancer patients to obtain the latest
most expensive standard of care therapeutics drugs due to
Governmental committee decisions, for example, as previously
reported for Velcade, Sorafenib, Abiraterone. The studies in
this manuscript, particularly those combining the generic drugs
Celebrex, Viagra and ATRA could thus become a cost-effective
approach to treat cancer patients with a wide variety of solid
malignancies in countries with limited ﬁnancial resources.
Based on the studies presented in this manuscript, it is hoped
that clinical translation of the two drug [celecoxib þ sildenaﬁl]
combination will occur in the near future.
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